Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6600+0.1800 (+5.17%)
At close: 04:00PM EDT
3.6600 0.00 (0.00%)
After hours: 04:49PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • M
    MFO
    Up with nice volume . 6 is a good target
    Bullish
  • M
    Michael Cho
    Today's Q-report was somewhat depressing .... forward-guidance was fairly weak. .... and without the Markets propping OPTN today, then OPTN is going to get hammered today. We expect it to go <$3.00 next week.
  • A
    AnEveryDay
    Our analysis concludes OPTN is the most de-risked small cap biotech on NASDAQ for FY2021. Actual Q3 2020 product revenues were $15.4MM (or $62MM annualized). OPTN trades for less than 4X actual revenues (not estimates). 6 professional analysts forecast FY2021 revenues between $90MM and $113MM (average = $104MM). Hence OPTN trades for roughly 2X FY2021 consensus. This is not an opinion. Investors can verify this for themselves here on Yahoo Finance. Investors should remember these revenue estimates are for the nasal polyp indication only and, for 2021, do not consider a chronic sinusitis label. OPTN has 2 Phase 3 trials for a chronic sinusitis indication that are expected to read in Q4 2021. The best part is one of the primary endpoints is subjective.

    OPTN estimates the chronic sinusitis market is about 10X the nasal polyp market. This means there are multiple roadmaps to $1Billion/year/sales. The best part is OPTN has noted a buyout is the most likely exit strategy to maximize shareholder value

    With peers trading for at least 4X FY2021 revenue estimates & 2 Phase 3 trials set to read in Q4 2021, this is the primary reason why RBC Capital & Cowen have $20 12-month share price targets.

    We can also confirm if OPTN hits 62% of their revenue targets and keep annual OPEX increases to 7.5%, OPTN has a pathway to break even and can repay the debt to terms. Liquidity is not an (immediate) concern.

    Our analysis concludes the worst case scenario is the trials completely fail & OPTN is auctioned to the highest bidder. A $60MM annual revenue stream (actual Q3 2020 revenues) should fetch at least $180MM (or 3X sales) in a fire sale. With a market cap of $210MM & EV of $185MM, remember the old saying about lack of downside. OPTN is our #1 pick for FY2021 (in small cap biotech).

    All the same, the short sales situation is an obvious red flag. We just started a large OPTN position. Therefore we would sincerely appreciate an OPTN short sharing their thesis. Why would shorting OPTN be a prudent investment?
    Bullish
  • M
    Mike T
    Stock price undervalued? Cash on hand is $145 million but market cap only $240 million? Prescription of Xhance also growing. Normalcy by next year. So, stock should start going up. Am I missing something? Or perhaps short sellers are manipulation?
  • j
    jackel
    Maybe it’s just me, but this new financing seems especially cruel to existing shareholders. 25 M new shares at a price per share lower than cash per share before the offering. There seems no great strategic purpose other than to put a lot of stock in play.
  • M
    Mr wolf
    Insider Victor M Clavelli reports buying 34,000 shares of
    $OPTN
    for a total cost of $104,040.00
  • l
    luv_those_mavs
    Huge accumulation from the tutes over past 6 months, buy or offer may be on way, up almost 50 % in past months, outstanding shares almost gone
  • O
    Old Man Logan
    Interesting news... this covid treatment could be used near term and help to reduce the disease burden... great add on that leverages the company's existing devices...
  • j
    john
    With millions of shares short, it would take a while to cover. An increase of a few cents wouldn’t indicate covering.
  • M
    Mr wolf
    Another bad day here , shorts playing their game , good entry point for new investors and average down at a discount price . Good days are coming . Stay long and strong 💪
    Bullish
  • l
    love
    The most telling thing about this whole situation is that management is still not buying their supposedly undervalued stock. What do they care when they are raking in high salaries without any performance standards. Each of the executive management teams salaries should have been reduced by 50% already, with stock compensation being awarded based on performance goals. This is a company I'm interested in, but don't think management is aligned with shareholders.
  • J
    J.A.M.E.S
    @AnEveryDay any thoughts on recent price action and today's outsized volume? I'm long OPTN and finally in the black after averaging down through the last 3-6 months downturn.
  • W
    Winston
    I ran across the below information. Normally when you see Hedge funds owning a stock you think the believe in the stock. However, you can’t always trust the Hedge Funds. The only gains from the below hedge fund Summer Value Partners’ was the money they stole from all of us shorting this small company and stealing our money we invested in this stock. They are playing the volume game with the stock..

    “While gathering more data about the company, we tracked down Summers Value Partners’ 3Q Investor Letter, in which, this boutique value manager talks about its position in the company:
    "The largest short position in the portfolio at the end of the third quarter was Optinose (OPTN). We have decided to unveil the name of the position at this time to provide greater clarity to our limited partners. The stock was a key contributor to performance in the third quarter and currently represents a material unrealized gain in the partnership. As a reminder, our goal on the short side is to generate positive absolute returns over the long term”
  • D
    Douglas
    27.00 here we come
  • F
    Frank
    In just 19 months, my investment in Optblows went from $30 per share to $4. In the meant time, the far overpaid Executive Team has raked in millions in comp as Rome Burned including a CFO making over $600K per year. They sold us a Billion Dollar company with a market value of less than 1/4 as they continue to sell stock to further dilute our holdings to finance their comp packages.
    My hats off to this scam company that is nothing but a source of Press Releases and Capital Losses.
    Bearish
  • M
    Mr wolf
    New institutions opening new positions...after Q2 report we should be north of $4 heading to $5. We need the big dogs to start buying to neutralize the shorts.
    Bullish
  • M
    Mr wolf
    Big Run coming 🚀🚀🚀OPN-019
    The company also is combining its EDS technology with an antiseptic for the treatment of COVID-19. In vitro testing demonstrated a 99.99% reduction in virus count. Initial release of the preclinical results caused a brief spike in OPTN shares to $10 in June 2020. The company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms in Mexico this April.
  • M
    Mr wolf
    Keep buying and loading the boat 🚤🚀🚀🚀💎🚀🚀🚀 short squeeze coming
    Bullish
  • R
    Re1n
    $WISH Short Squeeze | Power Hour | Stock Market Live 🚨
    www.youtube.com
    Bullish
Advertisement
Advertisement